The DOI matches its Crossref record; 199 of the 199 references it cites were found in a registry or an index.
Maintenance treatment with antipsychotic drugs for schizophrenia
Open accessAbstract
BACKGROUND: The symptoms and signs of schizophrenia have been firmly linked to high levels of dopamine in specific areas of the brain (limbic system). Antipsychotic drugs block the transmission of dopamine in the brain and reduce the acute symptoms of the disorder. This review examined whether antipsychotic drugs are also effective for relapse prevention. OBJECTIVES: To review the effects of maintaining antipsychotic drugs for people with schizophrenia compared to withdrawing these agents. SEARCH METHODS: We searched the Cochrane Schizophrenia Group's Specialised Register (November 2008), with additional searches of MEDLINE, EMBASE and clinicaltrials.gov (June 2011). SELECTION CRITERIA: We included all randomised trials comparing maintenance treatment with antipsychotic drugs and placebo for people with schizophrenia or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated relative risks (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. For continuous data, we calculated mean differences (MD) or standardised mean differences (SMD) again based on a random-effects model. MAIN RESULTS: The review currently includes 65 randomised controlled trials (RCT(s)) and 6493 participants comparing antipsychotic medication with placebo. The trials were published from 1959 to 2011 and their size ranged between 14 and 420 participants. In many studies the methods of randomisation, allocation and blinding were poorly reported. Although this and other potential sources of bias limited the overall quality, the efficacy of antipsychotic drugs for maintenance treatment in schizophrenia was clear. Antipsychotic drugs were significantly more effective than placebo in preventing relapse at seven to 12 months (primary outcome; drug 27%, placebo 64%, 24 RCT(s), n=2669, RR 0.40 CI 0.33 to 0.49, number needed to treat for an additional beneficial outcome (NNTB 3 CI 2 to 3). Hospitalisation was also reduced, however, the baseline risk was lower (drug 10%, placebo 26%, 16 RCT(s), n=2090, RR 0.38 CI 0.27 to 0.55, NNT 5 CI 4 to 9). More participants in the placebo group than in the antipsychotic drug group left the studies early due to any reason (at 7-12 months: drug 38%, placebo 66%, 18 RCT(s), n=2420, RR 0.55 CI 0.46 to 0.66, NNTB 4 CI 3 to 5) and due to inefficacy of treatment (at 7-12 months: drug 20%, placebo 50%, 18 RCT(s), n=2420, RR 0.36 CI 0.28 to 0.45, NNTB 3 CI 2 to 4). Quality of life was better in drug-treated participants (3 RCT(s), n=527, SMD -0.62 CI -1.15 to -0.09). Conversely, antipsychotic drugs as a group and irrespective of duration, were associated with more participants experiencing movement disorders (e.g. at least one movement disorder: drug 16%, placebo 9%, 22 RCT(s), n=3411, RR 1.55 CI 1.25 to 1.93, NNTH 25 CI 13 to 100), sedation (drug 13%, placebo 9%, 10 RCT(s), n=146, RR 1.50 CI 1.22 to 1.84, number needed to treat for an additional harmful outcome (NNTH) not significant) and weight gain (drug 10%, placebo 6%, 10 RCT(s), n=321, RR 2.07 CI 1.31 to 3.25, NNTH 20 CI 14 to 33). The results of the primary outcome were robust in a number of subgroup, meta-regression and sensitivity analyses, the main exception being that the drug-placebo difference in longer trials was smaller than in shorter trials. AUTHORS' CONCLUSIONS: The results clearly demonstrate the superiority of antipsychotic drugs compared to placebo in preventing relapse. This effect must be weighed against the side effects of antipsychotic drugs. Future studies should focus on outcomes of social participation and clarify the long-term morbidity and mortality associated with these drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Duval, S., & Tweedie, R. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00455.x · Cited by 14,099
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
The Global Assessment Scale: A Procedure for Measuring Overall Severity of Psychiatric Disturbance
Endicott, J. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770060086012 · Cited by 4,982
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561
Self-citationMoher, D. (2001) · JAMA · doi:10.1001/jama.285.15.1987 · Cited by 2,545
Remission in Schizophrenia: Proposed Criteria and Rationale for Consensus
Andreasen, N. C., Carpenter, W. T., Kane, J. M., Lasser, R. A., Marder, S. R., & Weinberger, D. R. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.3.441 · Cited by 2,343
Meta-analyses involving cross-over trials: methodological issues
Elbourne, D. R., Altman, D. G., Higgins, J. P., Curtin, F., Worthington, H. V., & Vail, A. (2002) · International Journal of Epidemiology · doi:10.1093/ije/31.1.140 · Cited by 2,305
Schizophrenia: A Concise Overview of Incidence, Prevalence, and Mortality
McGrath, J., Saha, S., Chant, D., & Welham, J. (2008) · Epidemiologic Reviews · doi:10.1093/epirev/mxn001 · Cited by 2,280
A Rating Scale for Drug-Induced Akathisia
Barnes, T. R. E. (1989) · British Journal of Psychiatry · doi:10.1192/bjp.154.5.672 · Cited by 2,170
Peters, J. L., Sutton, A. J., Jones, D. R., Abrams, K. R., & Rushton, L. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.11.010 · Cited by 2,053
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
Self-citationTiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354
Robinson, D., Woerner, M. G., Alvir, J. M. J., Bilder, R., Goldman, R., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., et al. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.3.241 · Cited by 1,327
International Consensus Study of Antipsychotic Dosing
Gardner, D. M., Murphy, A. L., O'Donnell, H., Centorrino, F., & Baldessarini, R. J. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09060802 · Cited by 1,301
Statistics Notes: Detecting skewness from summary information: Table 1
Altman, D. G., & Bland, J. M. (1996) · BMJ · doi:10.1136/bmj.313.7066.1200 · Cited by 1,278
LEUCHT, S., KANE, J., KISSLING, W., HAMANN, J., ETSCHEL, E., & ENGEL, R. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.04.008 · Cited by 1,226
Self-citationAtypical antipsychotic drugs and the risk of sudden cardiac death
Ray, W. A., Chung, C. P., Murray, K. T., Hall, K., & Stein, C. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806994 · Cited by 1,194
Risperidone in the treatment of schizophrenia
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.6.825 · Cited by 1,193
Morosini, P. L., Magliano, L., Brambilla, L., Ugolini, S., & Pioli, R. (2000) · PubMed · Cited by 1,168
Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., & Davis, J. M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60239-6 · Cited by 931
Self-citationMarwaha, S., & Johnson, S. (2004) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-004-0762-4 · Cited by 922
Clinical implications of Brief Psychiatric Rating Scale scores
Leucht, S., Kane, J. M., Kissling, W., Hamann, J., Etschel, E., & Engel, R. (2005) · British Journal of Psychiatry · doi:10.1192/bjp.187.4.366 · Cited by 896
Self-citationCHOUINARD, G., JONES, B., REMINGTON, G., BLOOM, D., ADDINGTON, D., MacEWAN, G. W., LABELLE, A., BEAUCLAIR, L., & ARNOTT, W. (1993) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199302000-00004 · Cited by 876
Marshall, M., Lockwood, A., Bradley, C., Adams, C., Joy, C., & Fenton, M. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.176.3.249 · Cited by 870
Gulliford, M. C., Ukoumunne, O. C., & Chinn, S. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009904 · Cited by 852
Bland, J. M., & Kerry, S. M. (1997) · BMJ · doi:10.1136/bmj.315.7108.600 · Cited by 754
The unit of analysis error in studies about physicians' patient care behavior
Divine, G. W., Brown, J. T., & Frazier, L. M. (1992) · Journal of General Internal Medicine · doi:10.1007/bf02599201 · Cited by 749
Drug and Sociotherapy in the Aftercare of Schizophrenic Patients: II. Two-Year Relapse Rates
Hogarty, G. E. (1974) · Archives of General Psychiatry · doi:10.1001/archpsyc.1974.01760170005001 · Cited by 573
Violence and schizophrenia: Examining the evidence
Walsh, E., Buchanan, A., & Fahy, T. (2002) · British Journal of Psychiatry · doi:10.1192/bjp.180.6.490 · Cited by 551
[The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use].
Boissel, J., Cucherat, M., Li, W., Châtellier, G., Gueyffier, F., Buyse, M. E., Boutitie, F., Nony, P., Haugh, M., & Mignot, G. (1999) · PubMed · Cited by 533
Leucht, S., Barnes, T. R. E., Kissling, W., Engel, R. R., Correll, C., & Kane, J. M. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.7.1209 · Cited by 517
Self-citationCarpenter, W. T., & Buchanan, R. W. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403103301006 · Cited by 510
II. A Randomised Controlled Trial of Prophylactic Neuroleptic Treatment
Crow, T. J., MacMillan, J. F., Johnson, A. L., & Johnstone, E. C. (1986) · British Journal of Psychiatry · doi:10.1192/bjp.148.2.120 · Cited by 491
Leucht, S., Komossa, K., Rummel-Kluge, C., Corves, C., Hunger, H., Schmid, F., Asenjo Lobos, C., Schwarz, S., & Davis, J. M. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08030368 · Cited by 490
Self-citationLeucht, S., Arbter, D., Engel, R. R., Kissling, W., & Davis, J. M. (2009) · Molecular Psychiatry · doi:10.1038/sj.mp.4002136 · Cited by 489
Neuroleptic Withdrawal in Schizophrenic Patients: A Review of the Literature
Gilbert, P. L. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950150005001 · Cited by 435
SLOF: a behavioral rating scale for assessing the mentally ill
Schneider, L. C., & Struening, E. L. (1983) · Social Work Research and Abstracts · doi:10.1093/swra/19.3.9 · Cited by 425
Leucht, C., Heres, S., Kane, J. M., Kissling, W., Davis, J. M., & Leucht, S. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2010.11.020 · Cited by 419
Self-citationOverview: maintenance therapy in psychiatry: I. Schizophrenia
(1975) · American Journal of Psychiatry · doi:10.1176/ajp.132.12.1237 · Cited by 410
Comprehensive Textbook of Psychiatry.
Grinker, R. R. (1967) · Archives of General Psychiatry · doi:10.1001/archpsyc.1967.01730290127021 · Cited by 401
Kishimoto, T., Robenzadeh, A., Leucht, C., Leucht, S., Watanabe, K., Mimura, M., Borenstein, M., Kane, J. M., & Correll, C. U. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs150 · Cited by 395
Self-citationXia (2009) · doi:10.1192/pb.bp.108.021949 · Cited by 381
Hogarty, G. E. (1979) · Archives of General Psychiatry · doi:10.1001/archpsyc.1979.01780120013001 · Cited by 365
Kane, J. M., Sanchez, R., Perry, P. P., Jin, N., Johnson, B. R., Forbes, R. A., McQuade, R. D., Carson, W. H., & Fleischhacker, W. W. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11m07530 · Cited by 361
Trial of Maintenance Therapy in Schizophrenia
Leff, J. P., & Wing, J. K. (1971) · BMJ · doi:10.1136/bmj.3.5775.599 · Cited by 338
Dose equivalence of the anti-psychotic drugs
Davis, J. M. (1974) · Journal of Psychiatric Research · doi:10.1016/0022-3956(74)90071-5 · Cited by 324
Self-citationSelf-report quality of life measure for people with schizophrenia: The SQLS
Wilkinson, G., Hesdon, B., Wild, D., Cookson, R., Farina, C., Sharma, V., Fitzpatrick, R., & Jenkinson, C. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.177.1.42 · Cited by 318
Pickar, D. (1986) · Archives of General Psychiatry · doi:10.1001/archpsyc.1986.01800070059008 · Cited by 318
Pigott, T. A., Carson, W. H., Saha, A. R., Torbeyns, A. F., Stock, E. G., Ingenito, G. G., & Aripiprazole Study Group (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0910 · Cited by 309
Antipsychotic Drugs: A New Risk Factor for Osteoporosis in Young Women With Schizophrenia?
O'Keane, V., & Meaney, A. M. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000150223.31007.e0 · Cited by 307
Diagnosis and Drug Treatment of Psychiatric Disorders
Ayd, F. J. (1969) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1969.03160180121024 · Cited by 305
Social functioning as an outcome measure in schizophrenia studies
Burns, T., & Patrick, D. (2007) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2007.01108.x · Cited by 305
Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology
Leon, A. C., Mallinckrodt, C. H., Chuang-Stein, C., Archibald, D. G., Archer, G. E., & Chartier, K. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.10.020 · Cited by 303
Drug and Sociotherapy in the Aftercare of Schizophrenic Patients: One-Year Relapse Rates
Hogarty, G. E. (1973) · Archives of General Psychiatry · doi:10.1001/archpsyc.1973.01750310038007 · Cited by 282
A self-rating scale of distress
Kellner, R., & Sheffield, B. F. (1973) · Psychological Medicine · doi:10.1017/s0033291700046377 · Cited by 281
Hough, D., Gopal, S., Vijapurkar, U., Lim, P., Morozova, M., & Eerdekens, M. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2009.10.026 · Cited by 265
Hirsch, S. R., Gaind, R., Rohde, P. D., Stevens, B. C., & Wing, J. K. (1973) · BMJ · doi:10.1136/bmj.1.5854.633 · Cited by 259
Tsuang, M. T. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770260031002 · Cited by 252
Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment
Viguera, A. C. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830130055011 · Cited by 246
Hogarty, G. E. (1974) · Archives of General Psychiatry · doi:10.1001/archpsyc.1974.01760170011002 · Cited by 242
Duggan, L., Fenton, M., Rathbone, J., Dardennes, R., El-Dosoky, A., & Indran, S. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001359.pub2 · Cited by 237
Moncrieff, J. (2006) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2006.00787.x · Cited by 231
Influence of antipsychotics on mortality in schizophrenia: systematic review
Weinmann, S., Read, J., & Aderhold, V. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.05.018 · Cited by 224
Kramer, M., Simpson, G., Maciulis, V., Kushner, S., Vijapurkar, U., Lim, P., & Eerdekens, M. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31802dda4a · Cited by 224
Fluphenazine vs Placebo in Patients With Remitted, Acute First-Episode Schizophrenia
Kane, J. M. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290010048009 · Cited by 222
Prediction of Relapse in Schizophrenic Outpatients Treated by Drug and Sociotherapy
Goldberg, S. C. (1977) · Archives of General Psychiatry · doi:10.1001/archpsyc.1977.01770140061008 · Cited by 218
Ran, M.-S., Xiang, M.-Z., Chan, C. L.-W., Leff, J., Simpson, P., Huang, M.-S., Shan, Y.-H., & Li, S.-G. (2003) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-003-0601-z · Cited by 195
Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia
Loo, H., Poirier-Littre, M.-F., Theron, M., Rein, W., & Fleurot, O. (1997) · British Journal of Psychiatry · doi:10.1192/bjp.170.1.18 · Cited by 195
Neuroleptic responsivity of negative and positive symptoms in schizophrenia
(1987) · American Journal of Psychiatry · doi:10.1176/ajp.144.12.1549 · Cited by 190
THE NORTHWICK PARK "FUNCTIONAL" PSYCHOSIS STUDY: DIAGNOSIS AND TREATMENT RESPONSE
Johnstone, E., Frith, C., Crow, T., & Owens, D. C. (1988) · The Lancet · doi:10.1016/s0140-6736(88)90682-4 · Cited by 186
Gitlin, M., Nuechterlein, K., Subotnik, K. L., Ventura, J., Mintz, J., Fogelson, D. L., Bartzokis, G., & Aravagiri, M. (2004) · FOCUS · doi:10.1176/foc.2.1.122 · Cited by 183
Arato, M., O??Connor, R., & Meltzer, H. Y. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200209000-00001 · Cited by 178
Prevention of Relapse in Schizophrenia: An Evaluation of Fluphenazine Decanoate
Schooler, N. R. (1980) · Archives of General Psychiatry · doi:10.1001/archpsyc.1980.01780140018002 · Cited by 177
Rifkin, A. (1977) · Archives of General Psychiatry · doi:10.1001/archpsyc.1977.01770130045004 · Cited by 175
LOSS TO OUTCOMES STAKEHOLDER SURVEY: THE LOSS STUDY
Xia, J., Adams, C. E., Bhagat, N., Bhagat, V., Bhoopathy, P., El-Sayeh, H., Pinfold, V., & Takritii, Y. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.02.451 · Cited by 173
Auquier, P., Simeoni, M. C., Sapin, C., Reine, G., Aghababian, V, Cramer, J., & Lançon, C. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(02)00355-9 · Cited by 162
Temporal Effects of Drug and Placebo in Delaying Relapse in Schizophrenic Outpatients
Hogarty, G. E. (1977) · Archives of General Psychiatry · doi:10.1001/archpsyc.1977.01770150055005 · Cited by 160
Treatment of Acute Psychosis Without Neuroleptics: Two-Year Outcomes From the Soteria Project
Bola, J. R., & Mosher, L. R. (2003) · The Journal of Nervous and Mental Disease · doi:10.1097/01.nmd.0000061148.84257.f9 · Cited by 159
Soteria: Evaluation of a home-based treatment for schizophrenia.
Mosher, L. R., Menn, A., & Matthews, S. (1975) · American Journal of Orthopsychiatry · doi:10.1111/j.1939-0025.1975.tb02556.x · Cited by 152
Chen, E. Y. H., Hui, C. L. M., Lam, M. M. L., Chiu, C. P. Y., Law, C. W., Chung, D. W. S., Tso, S., Pang, E. P. F., Chan, K. T., Wong, Y. C., et al. (2010) · BMJ · doi:10.1136/bmj.c4024 · Cited by 151
Effect of Risperidone on Hostility in Schizophrenia
Czobor, P., Volavka, J., & Meibach, R. C. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199508000-00002 · Cited by 151
Boyer, L., Siméoni, M.-C., Loundou, A., d’Amato, T., Reine, G., Lançon, C., & Auquier, P. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.05.019 · Cited by 149
Möller, H., Müller, H., Borison, R. L., Schooler, N. R., & Chouinard, G. (1995) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf02191543 · Cited by 147
Clozapine versus typical neuroleptic medication for schizophrenia
Wahlbeck, K., Cheine, M. V., & Essali, A. (1999) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000059 · Cited by 144
Is Disordered Thinking Unique to Schizophrenia?
Harrow, M., & Quinlan, D. (1977) · Archives of General Psychiatry · doi:10.1001/archpsyc.1977.01770130017001 · Cited by 141
Development and Prediction of Postpsychotic Depression in Neuroleptic-Treated Schizophrenics
Mandel, M. R. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290020051010 · Cited by 138
A depot neuroleptic withdrawal study
Wistedt, B., J�rgensen, A., & Wiles, D. (1982) · Psychopharmacology · doi:10.1007/bf00433729 · Cited by 134
Gäebel, W., Jänner, M., Frommann, N., Pietźcker, A., Köpcke, W., Linden, M., Müller, P., Müller-Spahn, F., & Tegeler, J. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00182-7 · Cited by 133
Hirsch, S. R., Bowen, J., Emami, J., Cramer, P., Jolley, A., Haw, C., & Dickinson, M. J. (1996) · The British Journal of Psychiatry · doi:10.1192/bjp.168.1.49 · Cited by 132
Community Residential Treatment for Schizophrenia: Two-Year Follow-up
Mosher, L. R., & Menn, A. (1978) · Psychiatric Services · doi:10.1176/ps.29.11.715 · Cited by 132
Extrapyramidal Symptoms in Patients Treated With Risperidone
Simpson, G. M., & Lindenmayer, J. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199706000-00010 · Cited by 132
Chemotherapy in Psychiatry: Principles and Practice
Seelye, E. E. (1986) · American Journal of Psychotherapy · doi:10.1176/appi.psychotherapy.1986.40.4.614 · Cited by 129
Chouinard, G. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199502001-00007 · Cited by 124
Srisurapanont, M., Maneeton, B., Maneeton, N., Lankappa, S. T., & Gandhi, R. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000967.pub2 · Cited by 122
The Scottish first episode schizophrenia study
McCreadie, R. G., Wiles, D., Grant, S. M., Crocket, G. T., Mahmood, Z., Livingston, M. G., Watt, J. A. G., Greene, J. G., Kershaw, P. W., Todd, N. A., et al. (1989) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1989.tb03032.x · Cited by 120
A depot neuroleptic withdrawal study
Wistedt, B. (1981) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1981.tb00761.x · Cited by 113
Relapse in Chronic Schizophrenics following Abrupt Withdrawal of Tranquilizing Medication
Prien, R. F., Cole, J. O., & Belkin§, N. F. (1969) · The British Journal of Psychiatry · doi:10.1192/bjp.115.523.679 · Cited by 111
Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia
Emsley, R., Nuamah, I., Hough, D., & Gopal, S. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.02.030 · Cited by 110
Discontinuation or reduction of chemotherapy in chronic schizophrenics
Caffey, E. M., Diamond, L. S., Frank, T. V., Grasberger, J. C., Herman, L., Klett, C. J., & Rothstein, C. (1964) · Journal of Chronic Diseases · doi:10.1016/0021-9681(64)90075-x · Cited by 110
Life Events and Maintenance Therapy in Schizophrenic Relapse
Leff, J., Hirsch, S. R., Gaind, R. N., Rohde, P., & Stevens, B. C. (1973) · The British Journal of Psychiatry · doi:10.1192/bjp.123.6.659 · Cited by 108
Gopal, S., Vijapurkar, U., Lim, P., Ma, M., Eerdekens, M., & Hough, D. W. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881110372817 · Cited by 103
The Dysphoric Syndrome in Schizophrenia and its Implications for Relapse
Hirsch, S. R., & Jolley, A. (1989) · The British Journal of Psychiatry · doi:10.1192/s0007125000295986 · Cited by 101
Early Neuroleptic Intervention in Schizophrenia: Are Prodromal Symptoms Valid Predictors of Relapse?
Gäebel, W., Frick, U., Köpcke, W., Linden, M., Müller, P., Müller-Spahn, F., Pietzcker, A., & Tegeler, J. (1993) · The British Journal of Psychiatry · doi:10.1192/s0007125000292416 · Cited by 100
d-Amphetamine-induced heterogeneous changes in psychotic behavior in schizophrenia
van Kammen, D. P., Bunney, W. E., Docherty, J. P., Marder, S. R., Ebert, M. H., Rosenblatt, J. E., & Rayner, J. (1982) · American Journal of Psychiatry · doi:10.1176/ajp.139.8.991 · Cited by 100
Chouinard, G., & Albright, P. S. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199708000-00010 · Cited by 97
The Scottish First Episode Schizophrenia Study
McCreadie, R. G., Wiles, D. H., Livingston, M. G., Watt, J. A. G., Greene, J. G., Kershaw, P. W., Todd, N. A., Scott, A. M., Crocket, G. T., Mahmood, Z., et al. (1992) · The British Journal of Psychiatry · doi:10.1192/bjp.161.4.496 · Cited by 95
Phenothiazines in Prevention of Psychiatric Hospitalization
Engelhardt, D. M., Rosen, B., Freedman, N., & Margolis, R. (1967) · Archives of General Psychiatry · doi:10.1001/archpsyc.1967.01730190100013 · Cited by 93
Clonidine treatment of schizophrenia
Freedman, R., Kirch, D. G., Bell, J. A., Adler, L. E., Pecevich, M., Pachtman, E., & Denver, P. (1982) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1982.tb00819.x · Cited by 91
Beasley, C. M., Sutton, V. K., Hamilton, S. H., Walker, D. J., Dossenbach, M. R. K., Taylor, C. C., Alaka, K., Bykowski, D., & Tollefson, G. D. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000095348.32154.ec · Cited by 91
I. Course of Illness, Stability of Diagnosis, and the Role of a Special Maintenance Clinic
Curson, D. A., Barnes, T. R. E., Bamber, R. W., Piatt, S. D., Hirsch, S. R., & Duffy, J. C. (1985) · The British Journal of Psychiatry · doi:10.1192/bjp.146.5.464 · Cited by 91
Hershon, H. I., Kennedy, P. F., & McGuire, R. (1972) · The British Journal of Psychiatry · doi:10.1192/bjp.120.554.41 · Cited by 91
Vernon, M., Revicki, D. A., Awad, A. G., Dirani, R. D., Panish, J. M., Canuso, C. M., Grinspan, A., Mannix, S., & Kalali, A. H. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.01.021 · Cited by 87
Safety Reporting in Randomized Trials of Mental Health Interventions
Papanikolaou, P. N., Churchill, R., Wahlbeck, K., Ioannidis, J. P. A., & The EU-PSI Project (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.9.1692 · Cited by 84
Pietźcker, A., Gäebel, W., Köpcke, W., Linden, M., Müller, P., Müller-Spahn, F., & Tegeler, J. (1993) · Journal of Psychiatric Research · doi:10.1016/0022-3956(93)90059-b · Cited by 83
Schizophrenics Fully Remitted on Neuroleptics for 3–5 years—To Stop or Continue Drugs?
Cheung, H. K. (1981) · The British Journal of Psychiatry · doi:10.1192/bjp.138.6.490 · Cited by 82
Dysphoric and depressive symptoms in chronic schizophrenia
Hirsch, S. R., Jolley, A., Barnes, T. R. E., Liddle, P. F., Curson, D. A., Patel, A., York, A., Berku, S., & Patel, M. (1989) · Schizophrenia Research · doi:10.1016/0920-9964(89)90002-9 · Cited by 81
Kane, J. M., Mackle, M., Snow‐Adami, L., Zhao, J., Szegedi, A., & Panagides, J. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10m06306 · Cited by 80
Episodic and Residual Thought Pathology in Chronic Schizophrenics: Effect of Neuroleptics
Spohn, H. E., Coyne, L., Larson, J., et al. (1986) · Schizophrenia Bulletin · doi:10.1093/schbul/12.3.394 · Cited by 77
Gopal, S., Gassmann-Mayer, C., Palumbo, J., Samtani, M. N., Shiwach, R., & Alphs, L. D. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903482772 · Cited by 74
TERMINATION OF CHLORPROMAZINE WITH SCHIZOPHRENIC PATIENTS
GOOD, W. W., STERLING, M., & Holtzman, W. H. (1958) · American Journal of Psychiatry · doi:10.1176/ajp.115.5.443 · Cited by 73
Matthews, S., Röper, M., Mosher, L. R., & Menn, A. (1979) · Schizophrenia Bulletin · doi:10.1093/schbul/5.2.322 · Cited by 72
DISCONTINUANCE OF TRANQUILIZERS AMONG CHRONIC SCHIZOPHRENIC PATIENTS RECEIVING MAINTENANCE DOSAGE
Diamond, L. S., & Marks, J. (1960) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-196009000-00006 · Cited by 67
Pope, A., Adams, C. E., Paton, C., Weaver, T. D., & Barnes, T. R. E. (2010) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.109.070961 · Cited by 61
Vaddadi, K. S., Gilleard, C. J., Mindham, R. H. S., & Butler, R. (1986) · Psychopharmacology · doi:10.1007/bf00180839 · Cited by 60
Greenberg, L. M., & Roth, S. D. (1966) · American Journal of Psychiatry · doi:10.1176/ajp.123.2.221 · Cited by 59
Withdrawal of Perphenazine in Chronic Schizophrenia
Whittaker, C. B., & Hoy, R. M. (1963) · The British Journal of Psychiatry · doi:10.1192/bjp.109.460.422 · Cited by 58
The effects of guided discontinuation of antipsychotics on neurocognition in first onset psychosis
Faber, G., Smid, H. G. O. M., Gool, A. R. V., Wiersma, D., & van den Bosch, R. J. (2011) · European Psychiatry · doi:10.1016/j.eurpsy.2011.02.003 · Cited by 58
Group Therapy and Maintenance Treatment of Schizophrenics
Claghorn, J. L. (1974) · Archives of General Psychiatry · doi:10.1001/archpsyc.1974.01760150069010 · Cited by 57
A Controlled Trial of Phenothiazine Withdrawal in Chronic Schizophrenic Patients
Andrews, P., Hall, J., & Snaith, R. P. (1976) · The British Journal of Psychiatry · doi:10.1192/bjp.128.5.451 · Cited by 57
Cooper, S. J., Butler, A., Tweed, J. A., Welch, C. P., & Raniwalla, J. (2000) · Psychopharmacology · doi:10.1007/s002130000452 · Cited by 55
Peuskens, J., Trivedi, J. K., Malyarov, S. A., Brecher, M., Svensson, O., Miller, F., Persson, I., & Meulien, D. (2007) · PubMed Central · Cited by 53
Quantitative Electroencephalogram Examination of Effects of Risperidone in Schizophrenic Patients
Czobor, P., & Volavka, J. (1993) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199310000-00006 · Cited by 53
The Scottish First Episode Schizophrenia Study V. One-year Follow-up
McCreadie, R. G., Wiles, D. H., Grant, S. M., MOORE, J. W., Crocket, G. T., Mahmood, Z., Livingston, M. G., Watt, J. A. G., Greene, J. G., Kershaw, P. W., et al. (1988) · The British Journal of Psychiatry · doi:10.1192/bjp.152.4.470 · Cited by 52
Anticholinergic Challenge and Neuroleptic Withdrawal
Gárdos, G. (1984) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790220020003 · Cited by 50
Tollefson, G. D., Dellva, M. A., Mattler, C. A., Kane, J. M., Wirshing, D. A., & Kinon, B. J. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199910000-00007 · Cited by 50
Branchey, M. H., Branchey, L., & RICHARDSON, M. A. (1981) · American Journal of Psychiatry · doi:10.1176/ajp.138.5.608 · Cited by 50
Tardive dyskinesia in schizophrenic patients treated with psychotropic drugs.
Crane, G. E. (1968) · PubMed · Cited by 47
Low dose fluphenazine decanoate in maintenance treatment of schizophrenia
Kane, J. M., Rifkin, A., Quitkin, F., Nayak, D., Saraf, K., Ramos-Lorenzi, J. R., Klein, D. F., & Sachar, E. J. (1979) · Psychiatry Research · doi:10.1016/0165-1781(79)90016-7 · Cited by 44
III. Relapse Postponement or Relapse Prevention? The Implications for Long-term Outcome
Curson, D. A., Barnes, T. R. E., Bamber, R. W., Platt, S. D., Hirsch, S. R., & Duffy, J. C. (1985) · The British Journal of Psychiatry · doi:10.1192/bjp.146.5.474 · Cited by 43
A Study of the Withdrawal of Chlorpromazine or Trifluoperazine in Chronic Schizophrenia
Morton, M. (1968) · American Journal of Psychiatry · doi:10.1176/ajp.124.11.1585 · Cited by 41
Schiele, B. C., Vestre, N. D., & Ke, S. (1998) · PubMed · Cited by 41
Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia
Lauriello, J., McEvoy, J. P., Rodriguez, S., Bossie, C. A., & Lasser, R. A. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.05.006 · Cited by 40
Gallant, D. M., EDWARDS, C. G., BISHOP, M. P., & Galbraith, G. C. (1964) · American Journal of Psychiatry · doi:10.1176/ajp.121.5.491 · Cited by 40
SUDDEN REMOVAL OF TRANQUILIZING DRUGS FROM CHRONIC PSYCHARIC PATIENTS
Olson, G. W., & Peterson, D. B. (1960) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-196009000-00007 · Cited by 40
Efficacy of risperidone on positive features of schizophrenia.
McEvoy, J. P. (1994) · PubMed · Cited by 39
Bai, Y., Yu, S.-C., & Lin, C.-C. (2003) · PubMed · Cited by 39
Risperidone for pre-existing severe tardive dyskinesia: a 48-week prospective follow-up study
Bai, Y., Yu, S.-C., Chen, J.-Y., Lin, C., Chou, P., & Lin, C.-C. (2005) · International Clinical Psychopharmacology · doi:10.1097/00004850-200503000-00003 · Cited by 39
Boonstra, G., Burger, H., Grobbee, D. E., & Kahn, R. S. (2011) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2010.534801 · Cited by 38
Markowitz, M., Fu, D., Levitan, B. S., Gopal, S., Turkoz, I., & Alphs, L. D. (2013) · Annals of General Psychiatry · doi:10.1186/1744-859x-12-22 · Cited by 38
Kozma, C. M., Slaton, T. L., Dirani, R. D., Fastenau, J. M., Gopal, S., & Hough, D. W. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.595000 · Cited by 38
van Kammen, D. P., Bunney, W. E., Docherty, J. P., Dc, J., Post, R. M., Siris, P. A. S. G., Ebert, M. H., & Gillin, J. C. (1977) · PubMed · Cited by 37
Abrupt withdrawal of Chlorpromazine and Thioridazine from Schizophrenic In-Patients
Melnyk, W. T., Worthington, A. G., & Laverty, S. G. (1966) · Canadian Psychiatric Association Journal · doi:10.1177/070674376601100507 · Cited by 37
Fleischhacker, W. W., Sanchez, R., Johnson, B. R., et al. (2013) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3283615dba · Cited by 35
Hui, C. L. M., Wong, G. H. Y., Tang, J. Y. ‐., Chang, W. C., Chan, S. K. W., Lee, E. H. M., Lam, M. M. L., Chiu, C. P. Y., Law, C. W., Chung, D. W. S., et al. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.08.010 · Cited by 35
Levine, J. A., Schooler, N. R., Severe, J. B., Escobar, J. I., Gelenberg, A. J., Mandel, M. R., Sovner, R., & Steinbook, R. M. (1980) · PubMed · Cited by 35
Efficacy of maintenance use of anticholinergic agents
Double, D. B., Warren, G. C., Evans, M., & Rowlands, R. P. (1993) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1993.tb03477.x · Cited by 34
Low Dose Medication Strategies in the Maintenance Treatment of Schizophrenia
Kane, J. M. (1983) · Schizophrenia Bulletin · doi:10.1093/schbul/9.4.528 · Cited by 33
Prolonged withdrawal of chlorpromazine in chronic patients.
Ls, F., & Alson, E. (1962) · PubMed · Cited by 33
Prophylactic effect of neuroleptics in symptom-free schizophrenics
Nishikawa, T., Tsuda, A., Tanaka, M., Koga, I., & Uchida, Y. (1982) · Psychopharmacology · doi:10.1007/bf00432759 · Cited by 32
Discontinuation of Neuroleptic Medication in Older, Outpatient Schizophrenics
Ruskin, P. E., & Nyman, G. E. (1991) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-199104000-00006 · Cited by 31
Sampath, G., Shah, A., Krska, J., & Soni, S. D. (1992) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.470070405 · Cited by 29
Wistedt, B., & Ranta, J. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09718.x · Cited by 29
Bernardo, M., Perea, J. R. A., Rubio-Terr??s, C., & Rejas, J. (2006) · Clinical Drug Investigation · doi:10.2165/00044011-200626080-00003 · Cited by 29
Kramer, M. L., Simpson, G. M., Mačiulis, V., Kushner, S. F., Liu, Y., Lim, P., Hough, D. W., Palumbo, J., & Eerdekens, M. (2010) · CNS Spectrums · doi:10.1017/s1092852900000456 · Cited by 28
Praag, H. M. V., & Dols, L. (1973) · American Journal of Psychiatry · doi:10.1176/ajp.130.7.801 · Cited by 27
Samtani, C., Sliwa, Fu, Turkoz, & Alphs, L. D. (2012) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s32581 · Cited by 27
Withdrawal of ataractic medication in schizophrenic patients.
Sl, G., Gershon, S., Sletten, I. W., et al. (1966) · PubMed · Cited by 27
Cessation of Medication for People With Schizophrenia Already Stable on Chlorpromazine
Almerie, M. Q., Matar, H. E., Essali, A., Alkhateeb, H. B., & Rezk, E. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm126 · Cited by 26
Minimal effective dose and relapse--double-blind trial: haloperidol decanoate vs. placebo.
Eklund, K. L., & Forsman, A. (1991) · PubMed · Cited by 24
Pimozide in chronic schizophrenic outpatients.
Clark, M. L., Huber, W. K., Hill, D., Wood, F., & Costiloe, J. P. (1975) · PubMed · Cited by 24
Withdrawal of Long-Term Phenothiazines from Chronically Hospitalized Psychiatric Patients
Marjerrison, G., Irvine, D. G., Stewart, C. N., et al. (1964) · Canadian Psychiatric Association Journal · doi:10.1177/070674376400900404 · Cited by 24
Wiedemann, G., Hahlweg, K., Müller, U., Feinstein, E., Hank, G., & Dose, M. (2001) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s004060170056 · Cited by 23
Lack of Behavioral Supersensitivity to d-Amphetamine After Pimozide Withdrawal
van Kammen, D. P. (1980) · Archives of General Psychiatry · doi:10.1001/archpsyc.1980.01780160057006 · Cited by 22
Cessation of medication for people with schizophrenia already stable on chlorpromazine
Almerie, M. Q., Alkhateeb, H. B., Essali, A., Matar, H. E., & Rezk, E. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006329 · Cited by 22
Withdrawal of antipsychotic drugs from chronic psychiatric patients.
Nc, R., Kondakis, X., Papanastassiou, A., et al. (1970) · PubMed · Cited by 21
Neuroleptic withdrawal in patients meeting criteria for supersensitivity psychosis.
Singh, H., Ji, H., Vitiello, B., & Gm, S. (1990) · PubMed · Cited by 21
Pickar, D., & Bartko, J. J. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.6.1133 · Cited by 20
Lack of tolerance to long‐term neuroleptic treatment in dopamine tuberoinfundibular system
Chouinard, G., Annable, L., Jones, B., & COLLU, R. (1981) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1981.tb00794.x · Cited by 18
Smelson, D. A., Tunis, S. L., Nyhuis, A. W., Faries, D. E., Kinon, B. J., & Ascher‐Svanum, H. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000245562.99036.92 · Cited by 16
Zwanikken, G. J. (1973) · PubMed · Cited by 14
El, D., & Jl, V. (1973) · PubMed · Cited by 12
Aripiprazole versus placebo for relapse prevention in patients with chronic schizophrenia
Carson, W., McQuade, R. D., Saha, A. R., Torbeyns, A. F., & Stock, E. G. (2002) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(02)80404-7 · Cited by 12
Bernardo, M., Azanza, Rubio‐Terres, C., & Rejas, J. (2007) · Actas Españolas de Psiquiatría · Cited by 9
Aripiprazole is effective for relapse prevention in people with chronic stable schizophrenia
Mortimer, P. A. M. (2004) · Evidence-Based Mental Health · doi:10.1136/ebmh.7.2.41 · Cited by 7
Critique of the Canadian Multicenter Placebo-Controlled Study of Risperidone and Haloperidol
Musser, W. S., & Kirisci, L. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199506000-00016 · Cited by 6
O'Connor, R., & Schooler, N. R. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(02)00309-2 · Cited by 4
Peuskens, J., Trivedi, J. K., Brecher, M., Svensson, O., Miller, F., & Meulien, D. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2007.12.027 · Cited by 3
Chen, Y. H., Hui, C. L. M., Lam, M. M. L., Law, C. W., Chiu, P. Y., Chung, W. S., Tso, S., Pang, P. F., Chan, K. T., Wong, Y., et al. (2008) · European Psychiatry · doi:10.1016/j.eurpsy.2008.01.760 · Cited by 3
Chen, E. Y. H., Hui, C. L. M., Lam, M. M. L., Law, C. W., Chiu, C. P. Y., Chung, D. W. S., Tso, S., Pang, E. P. F., Chan, K. T., Wong, Y., et al. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2007.12.020 · Cited by 2
Oosthuizen, P. (2003) · SUNScholar (Stellenbosch University) · Cited by 1
Avvisati, L., Rossi, R., Latte, G., Buonaguro, E. F., Eramo, A., Marmo, F., Tomasetti, C., Sarappa, C., Iasevoli, F., & de Bartolomeis, A. (2013) · European Psychiatry · doi:10.1016/s0924-9338(13)77115-3 · Cited by 1
Cited by
Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., & Davis, J. M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60239-6 · Cited by 931
Self-citationCorrell, C. U., & Schooler, N. R. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s225643 · Cited by 911
Leucht, S., Hierl, S., Kissling, W., Dold, M., & Davis, J. M. (2012) · British Journal of Psychiatry · doi:10.1192/bjp.bp.111.096594 · Cited by 451
Self-citationHasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & WFSBP Task force on Treatment Guidelines for Schizophrenia (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.739708 · Cited by 416
Guidelines for the Pharmacotherapy of Schizophrenia in Adults
Remington, G., Addington, D., Honer, W., Ismail, Z., Raedler, T., & Teehan, M. (2017) · The Canadian Journal of Psychiatry · doi:10.1177/0706743717720448 · Cited by 332
Metadata
- Authors
- Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., & Davis, J. M.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2012-05-16
- Volume
- 8
- Issue
- 5
- Pages
- CD008016-CD008016
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1541013958
- Cited by
- 290
- References
- 199
- FWCI
- 13.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.